BBC

Investor Moves

Name	Value	Action	Change	Price	Current Price
Ken GriffinCitadel Advisors $-1.6M ExitQ1 2026 $1.6M -- $43.70
Ken GriffinCitadel Advisors $-967.6K ExitQ4 2024 $968k -- $43.70
Ken GriffinCitadel Advisors $-967.6K ExitQ4 2024 $968k -- $43.70
Ken GriffinCitadel Advisors $-45.4K TrimQ3 2024 $45k -- $43.70
Ken GriffinCitadel Advisors $-45.4K TrimQ3 2024 $45k -- $43.70

News

defenseworld.netVirtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC) Sees Large Growth in Short Interestdefenseworld.netApr 19

zacks.comBiotech ETF (BBC) Touches Fresh 52-Week Highzacks.comApr 10

Trade BBC

About Virtus Biotech Clinical Trials ETF

This exchange-traded fund (ETF) endeavors to match the capital appreciation and income generation of the LifeSci Biotechnology Clinical Trials Index, disregarding fees and expenses. The underlying index focuses on tracking the financial progress of a carefully chosen group of biotechnology firms engaged in clinical trials. It is important to note that, as of February 27, the fund's official name transitioned from Virtus LifeSci Biotech Clinical Trials ETF to Virtus Biotech Clinical Trials ETF.

IPO Date: Dec 17, 2014

Market Data

Volume: 2.7K

Valuation

Valuation snapshot is not available yet.

Financials

Financial statement snapshot is not available yet.

Events

DividendDec 22

$0.65544